TIDMFARN
RNS Number : 1197Y
Faron Pharmaceuticals Oy
07 May 2019
NOTICE OF faron pharmaceuticals LTD's ANNUAL GENERAL MEETING
Shareholders of Faron Pharmaceuticals Ltd (the "Company") are
invited to attend the Annual General Meeting to be held on 28 May
2019 at 10.00 a.m. (Finnish time) at the BioCity building, Mauno
Conference Center, address Tykistökatu 6, 20520 Turku, Finland. The
registration of attendees and the distribution of voting slips will
commence at the meeting venue at 9.00 a.m. (Finnish time).
The Company's Annual Report 2018 is available to view and
download on the "Results" section of the Company's website at
https://www.faron.com/investors/results.
A. MATTERS ON THE AGA OF THE ANNUAL GENERAL MEETING
1. Opening of the meeting
2. Calling the meeting to order
3. Election of persons to scrutinise the minutes and to supervise the counting of votes
4. Recording the legality of the meeting
5. Recording the attendance at the meeting and adoption of the list of votes
6. Presentation of the financial statements, the Report of the
Board of Directors and the Auditor's Report for 2018
Review by the CEO; measures to remedy equity shortfall
7. Adoption of the financial statements
8. Resolution on the use of the profit shown on the balance sheet and the payment of dividend
The Board of Directors proposes that no dividend for the
financial year 2018 will be paid and that the losses of the Company
for the financial year, amounting to EUR 20,075,949.50 (IFRS), will
be carried forward to the reserve for invested unrestricted
equity.
9. Resolution on the discharge of the members of the Board of
Directors and the CEO of the Company from liability
10. Resolution on the remuneration of the members of the Board
of Directors
The Board of Directors proposes, on the basis of the proposal of
the Remuneration Committee, that an annual remuneration of EUR
35,000 will be paid to the Board members, in addition to which an
annual remuneration of EUR 35,000 will be paid to the Chairman of
the Board of Directors. In addition, a further annual remuneration
of EUR 11,000 will be paid to the Chairman of the Audit Committee,
a further annual remuneration of EUR 9,000 will be paid to the
Chairman of the Remuneration Committee and a further annual
remuneration of EUR 6,000 will be paid to the Chairman of the
Nomination Committee. In addition, a further annual remuneration of
EUR 6,000 will be paid to the Audit Committee members, a further
annual remuneration of EUR 5,000 will be paid to the Remuneration
Committee members and a further annual remuneration of EUR 3,000
will be paid to the Nomination Committee members.
The Board of Directors furthermore proposes that meeting fees
will be paid to the Board members as follows:
-- a meeting fee of EUR 1,000 will be paid to Board members per
Board meeting where the Board member was physically present and
which was held on another continent than the member's place of
residence; and
-- no meeting fees will be paid to Board members who were
attending a Board meeting but not physically present or for Board
meetings held on the same continent than the member's place of
residence.
In addition, it is proposed that all reasonable and properly
documented expenses incurred in the performance of duties of the
members of the Board of Directors would be compensated.
The Board of Directors also proposes, on the basis of the
proposal of the Remuneration Committee, that no remuneration will
be paid based on the Board membership of the CEO of the Company or
a person serving the Company under a full-time employment or
service agreement.
The Board of Directors notes that, in order to support the
Company's cost savings measures, the members of the Board of
Directors have voluntarily waived 20 per cent of their annual
remuneration and meeting fees between 1 July 2018 and 31 March
2019, the Company's CEO Markku Jalkanen has voluntarily agreed on a
salary reduction of 40 per cent between 1 June 2018 and 30 April
2019, and the Company's CFO Yrjö Wichmann has been laid off by 40
per cent between 16 July 2018 and 31 March 2019.
11. Resolution on the number of members of the Board of
Directors
The Board of Directors proposes on the basis of the proposal of
the Nomination Committee that seven (7) members be elected to the
Board of Directors.
12. Election of members of the Board of Directors
The Board of Directors proposes, on the basis of the proposal of
the Nomination Committee, that Frank Armstrong, Markku Jalkanen,
Matti Manner, Yrjö Wichmann, Leopoldo Zambeletti, Gregory Brown and
John Poulos be re-elected for a term that ends at the end of the
next Annual General Meeting.
Descriptions of the Board member candidates are available on the
Company's website:
https://www.faron.com/about-us/board-of-directors.
The proposed Board members have informed the Company that in the
event they are elected, they intend to elect Frank Armstrong as
Chairman of the Board and Matti Manner as Deputy Chairman of the
Board.
13. Resolution on the remuneration of the Auditor
The Board of Directors proposes, on the basis of the proposal of
the Audit Committee, that the Auditor be remunerated in accordance
with the invoice presented.
14. Election of the Auditor
The Board of Directors proposes, on the basis of the proposal of
the Audit Committee, that PricewaterhouseCoopers Oy, Authorised
Public Accountants, continue to act as the Company's auditor.
PricewaterhouseCoopers Oy has informed the Company that it will
appoint Panu Vänskä, Authorised Public Accountant, as the Auditor
with principal responsibility for the completion of the Audit.
15. Authorising the Board of Directors to decide on the issuance
of options or other special rights entitling to shares
The Board of Directors proposes, on the basis of the proposal of
the Remuneration Committee, that the Annual General Meeting
authorise the Board of Directors to resolve by one or several
decisions on issuances of options or other special rights entitling
to shares referred to in chapter 10, section 1 of the Finnish
Limited Liability Companies Act. The authorisation would consist of
up to 2,000,000 shares in the aggregate, which corresponds to
approximately 5.6 per cent of the existing shares and votes in the
Company.
The authorisation would not exclude the Board of Directors'
right to decide on the issuance of options or other special rights
entitling to shares in deviation from the shareholders' pre-emptive
rights. The authorisation is proposed to be used for implementing
an option plan for the employees and directors of, and persons
providing services to, the group, substantially in the form of the
option plan attached hereto as Annex 1. There is a weighty
financial reason for issuing options, as options are an integral
part of the incentivisation system for the management and personnel
of the Company.
Maximum number of options to be granted to the members of the
Company's management and the Board of Directors shall be as
follows:
-- to the Chairman of the Board, a maximum of 180,000 options;
-- to each member of the Board (excluding the Chairman of the
Board and the CEO and the CFO if they would be considered as
members of the Company's Board), a maximum of 90,000 options;
-- to the CEO, a maximum of 360,000 options; and
-- to the CFO, a maximum of 130,000 options.
The exercise of options will be subject to fulfilment of certain
criteria to be resolved by the Board of Directors (the "Exercise
Conditions").
Subject to fulfilment of the Exercise Conditions, the options
may be exercised at the exercise price, which may not be less than
the market value of a share at the grant date, as determined by the
Board of Directors (the "Exercise Price"). In determining such
market value, if shares are traded on the AIM market of the London
Stock Exchange, the Board of Directors shall have regard to the
average price per share at which shares have been so traded over a
period of 90 days immediately preceding the grant date. The
Exercise Price will be determined so as to create a sufficient
incentive for the recipients of options. The Exercise Price shall
be recorded in the Company's reserve for invested unrestricted
equity.
The Board of Directors would be authorised to resolve on all
other terms and conditions of the issuance of options or other
special rights entitling to shares referred to in chapter 10,
section 1 of the Finnish Limited Liability Companies Act.
The authorisation will be effective until 30 June 2023. This
authorisation shall not replace previous authorisations granted to
the Board of Directors.
16. Authorising the Board of Directors to decide on the issuance
of shares, options or other special rights entitling to shares
The Board of Directors proposes that the Annual General Meeting
authorise the Board of Directors to resolve by one or several
decisions on issuances of shares, options or other special rights
entitling to shares referred to in chapter 10, section 1 of the
Finnish Limited Liability Companies Act, which authorisation
contains the right to issue new shares or dispose of the shares in
the possession of the Company. The authorisation would consist of
up to 7,095,000 shares in the aggregate (including shares to be
received based on options or other special rights), which
corresponds to approximately 20 per cent of the existing shares and
votes in the Company.
The authorisation would not exclude the Board of Directors'
right to decide on the issuance of shares, options or other special
rights entitling to shares in deviation from the shareholders'
pre-emptive rights. The authorisation is proposed to be used for
material arrangements from the Company's point of view, such as
financing or implementing business arrangements, investments or for
other such purposes determined by the Board of Directors in which
case a weighty financial reason for issuing shares, and possibly
deviating from the shareholders' pre-emptive rights, would
exist.
The Board of Directors would be authorised to resolve on all
other terms and conditions of the issuance of shares, options or
other special rights entitling to shares.
The authorisation will be effective until 30 June 2020. This
authorisation shall not replace previous authorisations granted to
the Board of Directors.
17. Closing of the meeting
B. DOCUMENTS OF THE ANNUAL GENERAL MEETING
The above-mentioned proposals to the Annual General Meeting, the
Company's Annual Report 2018, including the financial statements,
the Report of the Board of Directors and the Auditor's Report, and
this notice are available immediately after publication of this
notice on the Company's website at
https://www.faron.com/investor-relations/annual-general-meeting-material.
The Board proposals and the other above-mentioned documents will
also be available at the Annual General Meeting. Copies of these
documents and of this notice will be sent to shareholders upon
request. The minutes of the Annual General Meeting will be
available to be viewed on the Company's website from 11 June 2019
at the latest.
C. INSTRUCTIONS FOR THE PARTICIPANTS
1. The right to participate and registration
Each shareholder who on the record date of the Annual General
Meeting, being 16 May 2019, is registered in the Company's
shareholders' register held by Euroclear Finland Ltd has the right
to participate in the Annual General Meeting. A shareholder whose
shares are registered on their personal book-entry account is
registered in the Company's shareholders' register.
A shareholder who is registered in the Company's shareholders'
register and who wants to participate in the Annual General Meeting
should register for the meeting by no later than 4 p.m. (Finnish
time) on Thursday 23 May 2019 by giving a prior notice of
participation:
-- by email to virve.nurmi@faron.com; or
-- by mail to Faron Pharmaceuticals Ltd, attn. Virve Nurmi,
Joukahaisenkatu 6, FI-20520 Turku, Finland.
When registering, a shareholder shall state their name, personal
identification number / business identity code, address, telephone
number and the name of a possible proxy representative or assistant
and the personal identification number of the proxy representative.
The personal data given by shareholders to the Company are used
only in connection with the Annual General Meeting and the
necessary processing of related registrations.
Shareholder, and their authorised representatives or proxy
representatives should, when necessary, be able to prove their
identity and/or right of representation.
2. Proxy representative and powers of attorney
Shareholders may participate in the Annual General Meeting and
exercise their rights at the meeting by way of proxy
representation. A proxy representative must present a dated power
of attorney or other reliable proof of their authority to represent
the shareholder.
A shareholder may participate in the Annual General Meeting by
means of several proxy representatives, who represent the
shareholder with shares held on different book-entry accounts. In
such case, the shares represented by each proxy representative
shall be identified when registering for the Annual General
Meeting.
Possible proxy documents should be sent in originals to Faron
Pharmaceuticals Ltd, Joukahaisenkatu 6, FI-20520 Turku, Finland
before the end of registration period.
3. Holder of nominee-registered shares (including depositary interest holders)
A holder of nominee-registered shares (including depositary
interest holders) has the right to participate in the Annual
General Meeting by virtue of such shares based on which the holder
would be entitled to be registered in the Company's shareholders'
register held by Euroclear Finland Ltd on the Annual General
Meeting's record date of 16 May 2019.
Additionally, participation requires that the holder of
nominee-registered shares is temporarily registered in the
Company's shareholders' register held by Euroclear Finland Ltd by
10 a.m. (Finnish time) on Thursday 23 May 2019. Temporary
registration in the shareholders' register shall be deemed to be a
registration for the Annual General Meeting.
Holders of nominee-registered shares are advised to request the
necessary instructions regarding the temporary registration in the
shareholders' register, the issuing of proxy documents and
registration for the General Meeting from their custodian bank
without delay. The account management organisation of the custodian
bank shall notify a holder of nominee-registered shares who wants
to participate in the Annual General Meeting to be temporarily
entered into the Company's shareholders' register by the
above-mentioned time.
4. Other instructions and information
Pursuant to chapter 5, section 25 of the Finnish Limited
Liability Companies Act, shareholders who are present at the Annual
General Meeting are entitled to request information regarding the
matters addressed by the meeting.
On the date of this notice, 7 May 2019, the total number of
shares and votes in the Company is 35,476,519.
The Annual General Meeting shall be held in Finnish and in
English.
Turku, 7 May 2019
FARON PHARMACEUTICALS LTD
Board of Directors
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulation (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Panmure Gordon (UK) Limited, Nomad and Broker
Emma Earl, Freddy Crossley (Corporate Finance)
James Stearns (Corporate Broking)
Phone: +44 207 886 2500
Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-mail: chris.brinzey@westwicke.com
About Faron Pharmaceuticals Ltd
Faron (AIM:FARN) is a clinical stage biopharmaceutical company
developing novel treatments for medical conditions with significant
unmet needs. The Company currently has a pipeline focusing on acute
organ traumas, vascular damage and cancer immunotherapy. The
Company's first candidate Traumakine, to prevent vascular leakage
and organ failures, has completed a Phase III clinical trial in
Acute Respiratory Distress Syndrome (ARDS). An additional European
Phase II Traumakine trial is underway for the Rupture of Abdominal
Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a
ground breaking early clinical anti-Clever-1 antibody. Clevegen has
the ability to switch immune suppression to immune activation in
various conditions, with potential across oncology, infectious
disease and vaccine development. This novel macrophage-directed
immuno-oncology switch called Turn-on-your-Immunity or Turn-It may
be used alone or in combination with other immune checkpoint
molecules for the treatment of cancer patients. Faron is based in
Turku, Finland. Further information is available at
www.faron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAEAFSKEDNNEAF
(END) Dow Jones Newswires
May 07, 2019 02:05 ET (06:05 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024